BUSINESS
Ami Organics: What should investors do, post recent correction?
BUSINESS
Food colour companies are in capacity overdrive. What next for investors?
BUSINESS
For Sumitomo Chemicals India, speciality is the trump card
BUSINESS
Fine Organics glued to green chemicals, may keep valuation premium
BUSINESS
What's the trump card for this speciality chemical player?
BUSINESS
Suven Pharma: Normalisation of margins adds to comfort
MONEYCONTROL-RESEARCH
Gland Pharma’s new product play for FY22 holds a lot of promise
BUSINESS
Rossari Biotech: Calibrated inorganic strategy opens up opportunities
BUSINESS
NOCIL: The end of capex cycle ups free cash flow prospects
BUSINESS
Divi’s Labs: Vertical integration keeps it ahead of peers
BUSINESS
Cadila: All in for COVID while keeping a tab on complex pharma
BUSINESS
Aarti Industries: Planning for a decade; accumulate
BUSINESS
Dr Reddy’s: COVID opportunity gets wings
BUSINESS
Lupin: Focus on inhalation and bio-similars to aid margins in medium term
BUSINESS
Anupam Rasayan IPO: A tiny version of PI Industries, diversifying beyond agro-chem
BUSINESS
Bodal Chemicals: Diversification towards benzene chemistry – a structural shift
BUSINESS
Hindustan Unilever: Can the elephant dance like a Pro?
BUSINESS
This food colour company’s business model makeover and capex plans need a close watch
BUSINESS
Cadila: a formidable play in Covid times and beyond
BUSINESS
Chemcon IPO: A strong import substitute play, but does it merit investors’ attention?
BUSINESS
Hikal: Focus on operational risk management adds to conviction
BUSINESS
Pharma: Trump’s executive orders may possibly provide better market access opportunities
ANNOUNCEMENTS
RIL AGM | Google on board; 5G ready
BUSINESS
Rossari Biotech: Healthy long-term prospects, but richly valued IPO
